A patient taking bupropion (Wellbutrin) 150 mg daily and aripiprazole (Abilify) 15 mg daily continues to have intrusive thoughts; should the aripiprazole dose be increased?

Do Not Increase Abilify - Reassess the Diagnosis and Treatment Strategy

The patient's intrusive thoughts on bupropion 150mg and aripiprazole 15mg should prompt a diagnostic reassessment rather than an automatic dose increase of aripiprazole, as intrusive thoughts are a hallmark of OCD, which requires SSRI-based treatment as first-line therapy, not antipsychotic augmentation. Moreover, aripiprazole itself can paradoxically cause or worsen obsessive-compulsive symptoms and intrusive thoughts in some patients 1, 2.

Critical Diagnostic Consideration

The current medication regimen suggests this patient may not have been properly diagnosed or treated for OCD:

• Bupropion (Wellbutrin) has no established role in treating OCD and is not mentioned in evidence-based OCD treatment algorithms 3
• Aripiprazole 15mg as monotherapy (with bupropion) is not first-line treatment for OCD - it is only indicated as augmentation of SSRIs in SSRI-resistant cases 3
• The presence of persistent intrusive thoughts suggests inadequate treatment of the underlying condition

The Aripiprazole Paradox: A Critical Safety Concern

Before increasing aripiprazole, consider that it may be causing rather than treating the intrusive thoughts:

• A 2024 systematic review found aripiprazole can induce obsessive-compulsive symptoms and other impulsive-compulsive behaviors, with symptoms typically appearing within 30 days of starting the medication 1
• These adverse effects occur at average doses of 11.63mg daily - well below the current 15mg dose 1
• Symptoms typically resolve within 30 days of discontinuation or dose reduction 1
• The FDA issued a 2016 warning about aripiprazole causing new impulse control problems 2

Evidence-Based Treatment Algorithm for OCD

According to the 2019 Nature Reviews Disease Primers OCD guidelines 3:

First-Line Treatment (which this patient has NOT received):

• SSRIs at maximum recommended or tolerated doses for at least 8 weeks - options include fluoxetine, sertraline, paroxetine, fluvoxamine, or escitalopram
• OR Cognitive Behavioral Therapy (CBT) with Exposure and Response Prevention (ERP) - 10-20 sessions

Second-Line for SSRI-Resistant OCD:

• Combine SSRI with CBT (if not already done)
• Switch to a different SSRI
• Trial of clomipramine (tricyclic antidepressant with strong serotonergic properties)
• Trial of SNRI (serotonin-norepinephrine reuptake inhibitor)

Third-Line - Augmentation Strategies:

Only after adequate SSRI trials, consider:

• Aripiprazole augmentation (added to SSRI, not as monotherapy) - meta-analysis shows evidence of efficacy 3
• Risperidone augmentation
• Glutamatergic agents (N-acetylcysteine, memantine)

Important caveat: Antipsychotic augmentation has a smaller effect size than SSRIs alone, with only one-third of SSRI-resistant patients showing clinically meaningful response 3. The risk-benefit ratio requires ongoing monitoring, particularly for metabolic side effects.

Recommended Clinical Action Plan

Step 1: Diagnostic Clarification

• Confirm OCD diagnosis using validated criteria
• Assess for comorbid conditions (depression, bipolar disorder, anxiety disorders)
• Rule out bipolar disorder - bupropion can trigger manic switching 4, and the presence of aripiprazole suggests mood instability may have been a concern

Step 2: Medication Adjustment

Do NOT increase aripiprazole. Instead:

1. Consider tapering and discontinuing aripiprazole to assess if it's contributing to intrusive thoughts 1
2. Initiate or optimize SSRI therapy - start with fluoxetine 40-80mg, sertraline 150-200mg, or paroxetine 40-60mg daily 3
3. Reassess bupropion's role - if treating comorbid depression, continue; if not clearly indicated, consider discontinuation as it has no anti-obsessional properties

Step 3: If SSRI Alone Insufficient After 8-12 Weeks

• Add CBT with ERP (most effective combination) 3
• OR switch to different SSRI or clomipramine
• OR consider SNRI trial

Step 4: Only If SSRI + CBT Fails

• Then consider low-dose aripiprazole augmentation (2-10mg) added to the SSRI 3, 5
• A 2022 meta-analysis found optimal aripiprazole dosing for augmentation is 2-5mg, with no additional benefit at higher doses 5
• Monitor closely for worsening obsessive-compulsive symptoms, metabolic effects, and akathisia

Special Considerations

If bipolar disorder is present: The treatment algorithm changes significantly 3. Mood stabilizers become primary, SSRIs must be used cautiously due to manic switching risk, and aripiprazole may be appropriate for mood stabilization. However, this still doesn't make it first-line for intrusive thoughts.

Monitoring parameters if aripiprazole is continued or reintroduced:

• New or worsening compulsive behaviors (gambling, shopping, sexual behaviors, eating) 1, 2
• Metabolic parameters (weight, glucose, lipids) 3
• Akathisia and extrapyramidal symptoms
• Blood pressure 6

Bottom Line

Increasing aripiprazole from 15mg in a patient with persistent intrusive thoughts is not evidence-based and may worsen the problem. The patient requires proper first-line OCD treatment with an SSRI (which they apparently have not received) and consideration that aripiprazole itself may be contributing to the intrusive thoughts. Only after documented SSRI resistance should low-dose aripiprazole augmentation (2-10mg, not 15mg+) be considered - and only as an addition to SSRI therapy, not as monotherapy with bupropion 3, 5.